Research indicates the importance of timely diagnosis in managing rare diseases — Evidence Review

A new study highlights ongoing challenges in diagnosing rare diseases and the critical need for improved diagnostic processes. The findings from the Dalla Lana School of Public Health align with extensive research showing that genomic advances are improving diagnosis rates, but significant barriers persist.

• Multiple studies confirm that genomic technologies like whole-exome and whole-genome sequencing have increased the diagnostic yield for rare diseases, but a substantial proportion of patients remain without answers, highlighting a persistent diagnostic gap 1 3 5 11 12.
• International and national initiatives have demonstrated that rare disease diagnosis rates improve with systematic approaches and data-sharing, yet access, validation of support tools, and integration into healthcare systems remain challenges 2 4 5 12.
• Delays in rare disease and cancer diagnoses are associated with worsened clinical outcomes, demonstrating the urgent need for streamlined pathways from symptom onset to accurate diagnosis 6 7 8 9 10.

Study Overview and Key Findings

Diagnosing rare diseases can take years, often leaving patients and families in uncertainty and delaying appropriate care. This study, reported by Hanan Hammad and colleagues from the Dalla Lana School of Public Health, underscores both the progress made and the gaps that persist in the rare disease diagnostic journey. The research is timely as advancements in genomics and data-sharing initiatives have raised expectations for faster, more precise diagnoses, but practical implementation still faces hurdles such as limited awareness, access to new tools, and the validation of diagnostic support systems.

Property	Value
Organization	Dalla Lana School of Public Health, Deloitte, Canadian Human Rights Commission
Authors	Hanan Hammad

Literature Review: Related Studies

We searched the Consensus paper database, which contains over 200 million research papers, to identify relevant studies on rare disease diagnosis and the impact of diagnostic delays. The following search queries were used:

1. rare disease diagnosis improvements
2. diagnostic delays impact on treatment
3. scientific advancements in rare disease identification

Literature Review Table

Topic	Key Findings
How are genomic technologies changing rare disease diagnosis?	- Next-generation sequencing (NGS) technologies, especially whole-exome and whole-genome sequencing, have increased rare disease diagnosis rates and enabled more personalized management for patients and families 1 5 11 12. - Additional technologies such as long-read sequencing, transcriptomics, and automated analysis further improve diagnosis, especially for cases unresolved by exome sequencing 3 13.
What are the consequences of diagnostic delays in rare and other diseases?	- Delayed diagnosis in rare diseases, cancers, and chronic illnesses is linked to disease progression, worse survival, and higher rates of complications or surgery 6 7 8 9 10. - Barriers to timely diagnosis include healthcare system fragmentation, lack of coordinated care, and insufficient access to diagnostic expertise, especially in lower-resource settings 9 10.
What is the impact and current state of diagnosis support systems?	- Computerized decision support systems and machine learning tools for rare disease diagnosis show promise, but require further validation and standardization for widespread clinical use 4. - International collaboration and data-sharing initiatives (e.g., IRDiRC, 100,000 Genomes Project) have improved gene discovery and diagnosis rates but highlight the need for reproducibility, data integration, and real-world implementation 2 5 12.
What are the remaining challenges in rare disease gene discovery?	- About half of rare disease genes remain undiscovered, and many patients still receive no molecular diagnosis even after comprehensive sequencing 2 11 12. - Ongoing research focuses on expanding gene catalogs, understanding non-coding variants, and integrating multi-omics data to bridge diagnostic gaps 3 11 12.

How are genomic technologies changing rare disease diagnosis?

Advancements in genomic technologies, particularly next-generation sequencing (NGS), have transformed the landscape of rare disease diagnosis. The new study's findings are consistent with prior research showing that incorporating whole-exome and whole-genome sequencing into clinical care increases diagnostic yields and provides actionable information for affected families 1 5 11 12. However, technological limitations and interpretation challenges mean that a significant number of cases remain unresolved.

• NGS has enabled higher diagnostic rates, especially for pediatric rare diseases, and supports better clinical management 1 5 11.
• When exome sequencing is inconclusive, technologies like long-read sequencing, whole-genome sequencing, and transcriptomics can identify additional disease-causing variants 3 13.
• Large-scale initiatives demonstrate that integrating genomic sequencing into national healthcare systems improves diagnosis rates and gene discovery 5 12.
• Despite progress, many rare disease cases remain undiagnosed, highlighting the need for continued development of analytical tools and broader access to genomic testing 3 11 12.

What are the consequences of diagnostic delays in rare and other diseases?

The reviewed research consistently shows that delays in diagnosis—whether for rare diseases, cancers, or chronic conditions—are associated with worse clinical outcomes and increased risk of complications. The new study's emphasis on the lengthy diagnostic journey for rare disease patients is reflected in broader evidence from other diseases 6 7 8 9 10.

• Long diagnostic intervals for rare diseases and cancers lead to disease progression, higher mortality, and greater healthcare utilization 6 7 8.
• Inflammatory bowel disease and various cancers demonstrate that later diagnosis increases the need for invasive interventions and reduces survival rates 8 10.
• Barriers such as healthcare fragmentation, costs, staffing shortages, and reliance on traditional medicine exacerbate delays, especially in low-resource settings 9.
• These findings underscore the importance of faster, more accurate diagnostic pathways for improving patient outcomes 7 8 9 10.

What is the impact and current state of diagnosis support systems?

Computerized diagnostic support systems and international data-sharing have become increasingly important in rare disease research. The new study’s call for improved diagnostic processes is echoed by evidence that, while these tools show promise, their real-world impact depends on validation, standardization, and integration into healthcare systems 2 4 5 12.

• Machine learning–based and expert-knowledge–driven support systems can enhance diagnostic accuracy, but require further validation and reproducibility studies 4.
• Online tools and phenotype-based query systems are emerging but need standardized evaluation to ensure reliability 4.
• International cooperation, such as through the IRDiRC and 100,000 Genomes Project, has accelerated gene discovery, diagnosis, and the move toward precision medicine 2 5 12.
• Successful integration of these systems into clinical workflows remains a challenge due to variability in approaches and lack of unified standards 4 5.

What are the remaining challenges in rare disease gene discovery?

Despite technological advances, a significant proportion of rare disease cases remain undiagnosed, and many causative genes are yet to be identified. The new study’s findings are in line with literature emphasizing ongoing research needs and the importance of multi-omics approaches 2 3 11 12.

• Roughly half of rare disease genes have not been identified, and many patients receive no molecular diagnosis even after advanced sequencing 2 11 12.
• Non-coding variants, structural variations, and regulatory mutations pose challenges for routine diagnostic pipelines 3 12.
• Integrating transcriptomics, metabolomics, and other omics data offers potential for uncovering additional disease mechanisms 3.
• Continued gene discovery efforts are critical for improving diagnostic rates and developing targeted therapies 2 11 12.

Future Research Questions

While recent advances have improved rare disease diagnosis rates, significant gaps remain. Future research is needed to address the persistent diagnostic odyssey, validate and scale up new technologies, and ensure equitable access for all patient populations.

Research Question	Relevance
How can diagnosis support systems for rare diseases be effectively validated and implemented in clinical practice?	Validation and real-world integration of computerized decision support tools are needed for consistent, reliable rare disease diagnosis. Current systems show promise but lack standardization and broad clinical use 4.
What are the most effective strategies to reduce diagnostic delays for rare diseases across different healthcare settings?	Diagnostic delays worsen outcomes; identifying interventions that work across diverse systems, including low-resource settings, will improve patient care 6 7 8 9 10.
How can multi-omics approaches be integrated into routine rare disease diagnosis?	Combining genomics, transcriptomics, metabolomics, and other omics may help diagnose cases unresolved by exome/genome sequencing, but implementation challenges remain 3 13.
What are the social and health system barriers to timely rare disease diagnosis, and how can they be overcome?	Non-technological factors—such as cost, care coordination, and access to expertise—play a major role in diagnostic delays, especially in underserved populations 9.
How can international data sharing and collaborative research accelerate the discovery of new rare disease genes?	International initiatives have improved gene discovery and diagnosis, but further collaboration, standardization, and data integration could close remaining gaps and speed up discovery 2 5 12.